EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Advances in the Diagnosis and Treatment of Myeloproliferative Neoplasms (MPNs)

Xinyu Ma, Zhibo Zhou, Shuyu Gu, Yan Guo, Tianqing Zhou, Ruonan Shao, Jinsong Yan iD, Wei Chen iD, Xiaofeng Shi iD

Cancers · 27.09.2025 · 17 (19) · 3142

DOI: 10.3390/cancers17193142 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 27.09.2025. Verfasst von Xinyu Ma und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing 210003, China. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 163 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Jiangsu Province College Students' Innovation and Innovation Training Program Project, Open Project of the Key Laboratory of Thrombosis and Hemostasis of the National Health Commission.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Myeloproliferative neoplasms (MPNs) encompass three principal subtypes: polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). These hematologic malignancies originate from clonal hematopoietic stem cells (HSCs) and exhibit pathological overproduction of myeloid lineage cells. Recent advances in molecular diagnostics, particularly the precise detection of core driver mutations (JAK2 V617F, CALR, and MPL) and non-driver mutations (ASXL1, TET2, SRSF2), has refined diagnostic precision and risk stratification. A variety of prognostic models for MPNs provide guidance for treatment. Treatment methods mainly include bloodletting therapy, low-dose aspirin anticoagulant therapy, cytoreductive therapy, and allogeneic hematopoietic stem cell transplantation (HSCT). JAK inhibitors (such as ruxolitinib) remain the basic therapeutic drugs. However, emerging strategies targeting epigenetic dysregulation and the interaction in the immune microenvironment (such as interferon-α) show promise in reducing drug resistance. New methods, including combination therapy (combination of JAK inhibitors and BCL-XL inhibitors) and mutation-independent immunotherapy, are under investigation. This review summarizes the latest advancements in the diagnosis and treatment of MPNs, highlighting the importance of molecular mechanisms in guiding therapeutic approaches and the potential for precision medicine in the future.

Schlagwörter

Stichwörter der Autor:innen

challenges and future directionsdiagnosis and treatmentdriver mutationsessential thrombocythemia (ET)myeloproliferative neoplasms (MPNs)polycythemia vera (PV)primary myelofibrosis (PMF)risk stratification

Autor:innen und Institutionen

  • Department of Hematology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing 210003, China.
  • The Second Clinical Medical School, Nanjing Medical University, Nanjing 210011, China.
  • Department of Hematology, Liaoning Medical Center for Hematopoietic Stem Cell Transplantation, The Second Hospital of Dalian Medical University, Dalian 116027, China.
  • Key Laboratory of Bone Marrow Stem Cells, Department of Hematology, Blood Diseases Institute, Affiliated Hospital of Xuzhou Medical University, No. 99, Western Huaihai Road, Xuzhou 221004, China.

ORCID-Profile: Jinsong Yan, Wei Chen, Xiaofeng Shi

Förderung

  • National Natural Science Foundation of China
  • Jiangsu Province College Students' Innovation and Innovation Training Program Project
  • Open Project of the Key Laboratory of Thrombosis and Hemostasis of the National Health Commission
  • Construction Project of High Level Hospital of Jiangsu Province
  • Jiangsu Province College Students’ Innovation and Innovation Training Program Project

Zitieren

APA

Ma, X., Zhou, Z., Gu, S., Guo, Y., Zhou, T., Shao, R., Yan, J., Chen, W., & Shi, X. (2025). Advances in the Diagnosis and Treatment of Myeloproliferative Neoplasms (MPNs). Cancers, 17(19), 3142. https://doi.org/10.3390/cancers17193142

Vancouver

Ma X, Zhou Z, Gu S, Guo Y, Zhou T, Shao R, et al. Advances in the Diagnosis and Treatment of Myeloproliferative Neoplasms (MPNs). Cancers. 2025;17(19):3142. doi:10.3390/cancers17193142

BibTeX
@article{Ma2025,
  author = {Ma, Xinyu and Zhou, Zhibo and Gu, Shuyu and Guo, Yan and Zhou, Tianqing and Shao, Ruonan and Yan, Jinsong and Chen, Wei and Shi, Xiaofeng},
  title = {Advances in the Diagnosis and Treatment of Myeloproliferative Neoplasms (MPNs)},
  journal = {Cancers},
  year = {2025},
  volume = {17},
  number = {19},
  pages = {3142},
  doi = {10.3390/cancers17193142}
}
Kostenlos starten →